08 Feb 2019 --- Sustainable ingredients company Amyris Inc. has signed a binding term sheet with an unnamed partner in an agreement valued at US$255 million for the development, licensing and commercialization of a new fermented cannabinoid. The deal is expected to be finalized by the end of March after which development of the cannabinoid will immediately begin. The commercialization of the cannabinoid products is reportedly expected within the next 18-24 months, assuming appropriate regulatory approvals.
